Diabetes
By pushing the boundaries of science and partnering with the NHS, AstraZeneca is committed to reducing the burden and complication of diabetes.
NHS Collaborations
Our collaborations - Oncology
Focussed on four scientific platforms, we are dedicated to scientific discovery and collaboration to help address unmet clinical needs in oncology.
For more information on specific NHS Collaborations, please click on the links below:
Provision of plasma testing in the EGFR mutation in patients with NSCLC in the UK
AstraZeneca has supported the provision of plasma testing for the EGFR and any associated EGFR T790M resistance mutation in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Business support: CMD imPACT Tool
The CMD imPACT project (a collaboration between The Royal College of Pathologists, Cancer Research UK and the ABPI Pharmaceutical Oncology Initiative (POI) brought together complementary expertise from the three partner organisations to improve patient outcomes. This project aimed to support the delivery of stratified medicine in the NHS.
One of the resources developed by the project was the CMD imPACT business planning tool. The tool is a simple Microsoft Excel-based software program that has been developed to improve patient outcomes by exploring cost efficiencies and analysis for practical planning. It acts as an adaptable business case template for laboratories to apply for more diagnostics funding.
Disease Areas
Respiratory Disease
We are incredibly proud of our 40+ year heritage in respiratory disease. By delivering scientific breakthoughs and working collaboratively with the NHS, we have improved the lives of people living with asthma and COPD in the UK.
Cardiovascular disease
AstraZeneca has a rich heritage in partnering with the NHS to improve the lives of patients with cardiovascular disease.
VVPM ID: GB-14982 Date of Prep: December 2018